BRAIN Biotech AG (BNN)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 2.760 |
|---|---|
| 52-week range | 2.110 – 3.740 |
| Return, 1 month / 3 months | −1.1% / −0.7% |
| Return, 1 year / 3 years | +22.7% / −24.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 68.4% |
| Worst drawdown (1 year) | -41.0% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BRAIN Biotech AG is a German industrial biotechnology company that develops enzymes, microorganisms and bioactive compounds for industrial customers. It supplies specialised enzyme products and microbial strains used in food, feed, chemical and pharmaceutical manufacturing, and it runs a contract research business offering screening, bioinformatics and strain development services to partner companies. The company is based in Germany and works with clients across Europe and beyond on biological solutions for industrial production.
BRAIN Biotech AG trades under the code BNN on the Deutsche Börse Xetra in Germany, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BRAIN Biotech AG (BNN) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 2.760 on 27 October 2026.
Its price-based Market X-Ray is 43 out of 100 (a weak price profile), ranking 455 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 22.7% and over the last three months it fell 0.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.5% | ||
| From 52-week high | -24.6% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.7% | ||
| 6-month return | 10.0% | ||
| 12-month return, skipping the last month | 24.0% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 68.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.0% | ||
| Liquidity | 24 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −1.1% |
| 3 months | −0.7% |
| 6 months | +10.0% |
| 1 year | +22.7% |
| 3 years | −24.8% |
| 5 years | −71.9% |
Signals
| 50-day / 200-day average | 2.774 / 2.692 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.147 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.